FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the 27th Annual Piper Jaffray Healthcare Conference in New York on December 2nd, 2015 at 12:50 pm EST.
About Castle Biosciences
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow-up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with uveal melanoma (DecisionDx-UM), cutaneous melanoma (DecisionDx-Melanoma) and esophageal cancer (DecisionDx-EC), among others. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.castlebiosciences.com.
DecisionDx-UM, DecisionDx-Melanoma and DecisionDx-EC are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.